Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals Inc. is set to participate in the 2024 Jefferies Global Healthcare Conference in New York, where it will engage in one-on-one investor meetings and give a presentation scheduled for June 5. The company will also provide a live webcast of the event accessible via their website. Aurinia is recognized for introducing LUPKYNIS, the first FDA-approved oral treatment for adult lupus nephritis patients, and operates globally with a focus on autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
